Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-D46/EVOKE-03: pembrolizumab + sacituzumab govitecan versus pembrolizumab first-line for PD-L1-high metastatic non-small cell lung cancer
2022-000836-49Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Pembrolizumab + sacituzumab govitecan with Pembrolizumab monotherapy (2 arms). Primary endpoint: Progression-Free Survival. Started Oct 2022; status: active.
02
Drugs
pembrolizumabsacituzumab govitecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-000836-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000836-49.